Mycenax Biotech Inc. (TPEX:4726)

Market Cap	8.36B
Revenue (ttm)	725.45M
Net Income (ttm)	-460.65M
Shares Out	207.22M
EPS (ttm)	-2.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	258,604
Average Volume	387,283
Open	40.35
Previous Close	40.35
Day's Range	39.50 - 40.50
52-Week Range	27.40 - 65.20
Beta	0.66
RSI	64.66
Earnings Date	Aug 12, 2025

About Mycenax Biotech

Mycenax Biotech Inc., a contract development and manufacturing organization company, provides biopharmaceutical services and solutions for drug development and production in Taiwan, Japan, Korea, Singapore, rest of the Asia-Pacific regions, Europe, and the United States. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-dru...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 387
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4726

Financial Performance

In 2024, Mycenax Biotech's revenue was 683.92 million, an increase of 4.80% compared to the previous year's 652.62 million. Losses were -467.13 million, -31.59% less than in 2023.